News
MXCT
1.130
-13.08%
-0.170
MaxCyte (MXCT) Q3 2026 Earnings Call Transcript
The Motley Fool · 5h ago
MaxCyte Q3 2026 Earnings Call Transcript
Benzinga · 13h ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 13h ago
MaxCyte falls after $151.8M deal to buy Akron Bio for cash and stock
Seeking Alpha · 17h ago
MaxCyte to acquire Akron BioProducts for $151.8M
TipRanks · 17h ago
MaxCyte reports Q3 EPS (5c), consensus (8c)
TipRanks · 17h ago
MaxCyte Reports Strong Third-Quarter Revenue Growth and Narrower Loss
TipRanks · 21h ago
MaxCyte FY2026 Revenue expected to be more than $34.500M vs $32.211M Est
Benzinga · 21h ago
MaxCyte To Acquire Akron
NASDAQ · 23h ago
MaxCyte, Inc. Q3 Loss Declines
NASDAQ · 1d ago
MaxCyte To Acquire Akron BioProducts From Arcline Investment Management For Total Consideration Of $151.8M, Comprising $105M In Cash And 20.6M MXCT Shares Worth ~$26.8M
Benzinga · 1d ago
MaxCyte beats Q3 EPS and revenue estimates, issues FY revenue guidance above consensus
Seeking Alpha · 1d ago
*MaxCyte to Pay $105 Million Cash, 20.6 Million Shares at Closing >MXCT
Dow Jones · 1d ago
*MaxCyte to Pay $20 Million in Guaranteed Deferred Payments >MXCT
Dow Jones · 1d ago
*MaxCyte To Buy Akron BioProducts From Arcline Investment Management for $151.8 Million >MXCT
Dow Jones · 1d ago
*MaxCyte 3Q Rev $10.2M >MXCT
Dow Jones · 1d ago
Press Release: MaxCyte Reports Third Quarter 2026 -2-
Dow Jones · 1d ago
*MaxCyte 3Q Loss/Shr 5c >MXCT
Dow Jones · 1d ago
*MaxCyte: Akron Bio Expected to Generate About $28 Million in 2026 Revenue >MXCT
Dow Jones · 1d ago
Press Release: MaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue Guidance
Dow Jones · 1d ago
More
Webull provides a variety of real-time MXCT stock news. You can receive the latest news about Maxcyte through multiple platforms. This information may help you make smarter investment decisions.
About MXCT
MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.